IGIV Manufacturer Letters Should Be Ignored During FDA Review, Agency Says
Executive Summary
Prescriber letters sent by immune globulin intravenous manufacturers asserting superiority over other IGIV products should be disregarded while FDA completes its safety review of thrombotic events, the agency said